Two Roads to In Vivo CAR-T: The Viral versus Lipid Nanoparticle sprint, Who will win the race?

CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to isolate and manipulate T cells outside of the patient. This in vivo CAR-T engineering is a game changer and has significantly reduced the time to patient treatment. Join Joseph Brealey to find out more about in vivo CAR-T reprogramming approaches and how multiple analytics is consolidated into a single workflow, saving time and cost without compromising data quality for your CAR therapy research and development. Learning Objectives: Advantages over traditional ex vivo CAR T cell therapy Strategies for improving quality control of in vivo CAR T therapies Streamline your workflow with combine ligand and mRNA cargo characterization to a single run for in vivo CAR delivery vehicle Speaker: Joseph Brealey - Nanoparticles Analytical Scientist